| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From the Departments of Surgery (VJV, FANZ), Gastroenterology (HB), Radiotherapy (BMPA), and Biometrics (HVT), The Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Correspondence: Address correspondence and reprint requests to: Vic J. Verwaal, MD, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands; Fax: 31-20-5122554; E-mail: v.verwaal{at}nki.nl
Background: After treatment of peritoneal carcinomatosis of colorectal cancer origin by cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC), recurrences develop in approximately 80% of patients. This study evaluates the outcome of such recurrences after initial treatment by cytoreduction and HIPEC.
Methods: Between November 1995 and May 2003, 106 patients underwent cytoreduction and HIPEC. The progression-free interval, the location of the recurrence, and its treatment were recorded. Factors potentially related to survival after recurrences were studied.
Results: Sixty-nine patients had a recurrence within the study period. For patients who had undergone a gross incomplete initial cytoreduction, the median duration of survival after recurrence was 3.7 months (standard error of the mean [SE], .3). If a complete cytoreduction had been accomplished initially, the median duration of survival after the recurrence was 11.1 months (SE, .9). A shorter interval between HIPEC and recurrence was associated with shorter survival after treatment of recurrence (hazard ratio, .94; SE, .02). After effective initial treatment, a second surgical debulking for recurrent disease resulted in a median survival duration of 10.3 months (SE, 1.9), and after treatment with chemotherapy it was 8.5 months (SE, 1.6). The survival was 11.2 months (SE, .5) for patients who received radiotherapy for recurrent disease. Patients who did not receive further treatment survived 1.9 months (SE, .3).
Conclusions: Treatment of recurrence after cytoreduction and HIPEC is often feasible and seems worthwhile in selected patients. Selection should be based mainly on the completeness of initial cytoreduction and the interval between HIPEC and recurrence.
Key Words: Chemotherapy • Colorectal cancer • HIPEC • Intraperitoneal chemotherapy • Peritoneal carcinomatosis • Recurrence
This article has been cited by other articles:
 |
|
 |
|
  T. D. Yan, J. Sim, and D. L. Morris Selection of Patients with Colorectal Peritoneal Carcinomatosis for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy Ann. Surg. Oncol., June 1, 2007; 14(6): 1807 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Aarts, M. J. Koppe, T. Hendriks, J. E. M. vanEerd, W. J. G. Oyen, O. C. Boerman, and R. P. Bleichrodt Timing of Adjuvant Radioimmunotherapy after Cytoreductive Surgery in Experimental Peritoneal Carcinomatosis of Colorectal Origin Ann. Surg. Oncol., February 1, 2007; 14(2): 533 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Koppe, T. Hendriks, O. C. Boerman, W. J.G. Oyen, and R. P. Bleichrodt Radioimmunotherapy Is an Effective Adjuvant Treatment After Cytoreductive Surgery of Experimental Colonic Peritoneal Carcinomatosis J. Nucl. Med., November 1, 2006; 47(11): 1867 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Yan, D. Black, R. Savady, and P. H. Sugarbaker Systematic Review on the Efficacy of Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal Carcinoma J. Clin. Oncol., August 20, 2006; 24(24): 4011 - 4019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Levine Editorial: Problems of Success and Problems of Failure: Recurrent Disease After Cytoreductive Surgery and Intraperitoneal Chemoperfusion Ann. Surg. Oncol., April 1, 2004; 11(4): 351 - 353. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
